Medical device reshoring is moving from contingency planning to a strategic response to 10%–25% or higher tariffs on selected products and components, with domestic final assembly unable to remove duties on imported inputs [S4].
The 2026 decision is not simply whether to manufacture closer to customers, but which processes to relocate, how to qualify suppliers, and how to maintain a digital quality thread across the United States, Mexico, Costa Rica, Puerto Rico, and allied production sites [S2][S4].
Why manufacturers are changing production geography
Tariffs, supply interruptions, and stronger quality oversight are making medical device manufacturing geography a board-level operating decision rather than a procurement preference [S4]. Tariff exposure depends on the country of origin and product category, and imported sensors, printed-circuit-board assemblies, housings, and Nitinol tubing can remain dutiable even after final assembly moves into the United States [S4].
Quality-system requirements add another constraint. The FDA Quality Management System Regulation, effective February 2, 2026, incorporates ISO 13485:2016 by reference and increases scrutiny of supplier controls, outsourced processes, and access to documentation during inspections [S4]. Europe’s MDR and IVDR adaptation likewise remain active considerations for manufacturers operating across jurisdictions [S2].
Supply fragility adds a patient-safety dimension. Disruptions from pandemic-era shortages, Red Sea shipping disruption during 2023–2025, and 2026 Strait of Hormuz tensions showed that an extended global chain can produce medical-device shortages, not merely delayed orders [S4]. The result is a structural shift from single-region sourcing toward dual sourcing, regional capacity buffers, and diversified production networks [S2][S4].
Reshoring, nearshoring, and friend-shoring compared
Reshoring, nearshoring, and friend-shoring differ on location, operating control, logistics, tariff exposure, and labor cost, making a hybrid network more practical than moving an entire bill of materials into one country [S4].
Relocating final assembly to the United States does not eliminate tariffs on imported components [S4].
Which manufacturing scopes should move

Component selection must follow device requirements rather than country labels. Relevant PTFE tubing examples include inner diameters from 0.010 inch to 0.155 inch, while the cited Ultra PI material is described as providing nearly twice the strength of traditional polyimide without sacrificing inner-lumen space [S5]. These are material-specific facts, not universal properties of every polymer or device, so engineers should validate them against the finished-device design and intended use [S5].
Reshoring work also includes retooling, redesigning, re-sourcing, and rebuilding the supply chain, all of which require time and capital [S7]. Modularity can improve operational agility, while vertically integrated operations for Nitinol components, polymer tubing, and balloon catheters can reduce third-party dependencies, lead times, and quality risk, but they also concentrate capital and maintenance requirements in fewer internal processes [S5][S6].
Digital traceability is a production prerequisite
Distributed manufacturing turns disconnected quality records into a direct operational liability because companies must trace components, monitor supplier quality, and respond to disruptions across more than one production network [S2].
The connected record now spans design, manufacturing, quality, and postmarket systems; in February 2026, the FDA’s QMSR entered full effect with alignment to ISO 13485:2016 [S2]. These systems create verifiable links among supplier qualifications, lot records, nonconformance decisions, released devices, and postmarket information [S2].
For procurement teams, this changes the supplier questionnaire. A nominal supplier qualification is insufficient if the manufacturer cannot retrieve component genealogy, process evidence, and quality records across regional plants. A practical bid should specify the UDI and lot-data interface, change-notification process, document-access conditions, validation evidence, and responsibility for correction or preventive action, with the applicable QMSR and ISO 13485:2016 obligations retained in the purchasing process [S2][S4].
Use cases where regional production earns its complexity

Domestic final assembly fits products with frequent quality events, short replacement cycles, government-contract sensitivity, or high consequences from a stockout, because it reduces physical distance between manufacturing, investigation, and replenishment [S4]. The approach is also relevant to production requiring strong coordination among machining, molding, electronics assembly, cleanroom processes, sterilization, packaging, and release testing [S6].
Nearshoring is more defensible for bulky or transport-sensitive products and for components where geography shortens logistics without requiring a complete U.S. supply network [S4]. Mexico, Costa Rica, and Puerto Rico offer proximity and time-zone alignment, but each destination adds jurisdiction-specific regulatory and infrastructure requirements [S4]. Friend-shoring can diversify exposure across Canada, India, Poland, or Vietnam, although it retains longer logistics routes than nearshoring [S4].
Customized devices also strengthen the case for flexible regional supply. Structural-heart delivery systems, neurovascular devices, implantable textiles, catheters, and other high-complexity products require combinations of stiffness, flexibility, torque response, strength, and fatigue resistance that cannot be evaluated by unit cost alone [S5]. Miniaturization raises the verification burden because small dimensions leave less tolerance for dimensional variation and demand tighter process control [S5].
Failure modes and limits of a reshoring program
The main failure mode is treating final assembly relocation as tariff elimination. A device assembled in the United States can still incur import duties on every foreign-sourced component, with rates illustrated at 10% for German sensors, 15% for Taiwanese PCB assemblies, and 25% or more for Chinese Nitinol tubing [S4].
A second failure mode is adding sites before unifying master data and UDI records. Dispersed production without a reliable digital thread can weaken consistent quality control, delay supplier investigations, and prevent rapid root-cause analysis [S2]. A third is assuming that domestic capacity is interchangeable across product families: the reshoring framework identifies limited domestic capacity for some component types and higher labor and operating costs as structural constraints [S4].
Reshoring is therefore unsuitable as a blanket response to every supply-chain problem. It is strongest when the cost of delay, quality-event response, or stockout risk is measurable, and when the product supply chain can be decomposed into components suitable for regional production. It is weaker when low-cost labor dominates value, critical inputs have no qualified alternate source, or tariff and compliance calculations remain unresolved at component level [S4].
How to build and verify the sourcing decision

A defensible reshoring decision requires a component-level tariff map, a site-level quality risk assessment, and a validated digital record architecture. The first analytical step is to map each bill-of-materials item to origin, applicable tariff rate, sole- or dual-source status, qualification lead time, and inventory buffer [S2][S4].
The second step is to compare at least four decision criteria: landed cost including tariffs, quality and regulatory control, disruption recovery time, and supplier or site capacity. Final assembly location alone cannot answer the trade-off because a lower assembly cost can be offset by tariffs on sensors, PCBs, housings, or Nitinol tubing [S4].
The third step is validation. Production changes should include supplier qualification, process validation where required, updated control plans, material and lot traceability, UDI linkage, and documented supplier-change controls under the QMSR and ISO 13485:2016 framework [S2][S4]. Track four operational signals after implementation: imported-component duty as a percentage of product value, number of single-source critical components, time required to retrieve a lot’s quality record, and recovery time after a supplier interruption.
By the end of 2026, the clearest evidence that reshoring is working will not be the number of announcements or facilities opened, but whether manufacturers can operate multi-site production with traceable components, qualified suppliers, rapid disruption response, and a defensible landed-cost model [S2][S4].